Composition and dosage form comprising opioid antagonist
First Claim
Patent Images
1. An osmotic dosage form comprising:
- (a) a wall comprising a semipermeable composition, which wall surrounds;
(b) a bilayer core comprising;
(i) a first layer comprising 75 ng to 750 mg of an analgesic opioid;
(ii) a second push-displacement layer in bilayered contact with the first layer comprising 40 to 99 wt % of a poly(alkylene oxide) possessing a number-average molecular weight to 10,000,000, and 0.25 to 25 wt % of a hydroxyalkylcellulose possessing a number-average molecular weight to 75,000, and wherein the second layer is characterized by comprising 0.75 to 10 wt % of an antagonist selected from the group consisting of naltrexone, naloxone, nalmefene, nalide, nalmexone, nalorphine and nalbuphine; and
,(c) an exit in the wall in contact with the first layer comprising the analgesic opioid for the push-displacement layer to push the first layer comprising the analgesic opioid through the exit from the dosage form.
1 Assignment
0 Petitions
Accused Products
Abstract
A composition of matter is disclosed and claimed comprising an opioid antagonist and a high molecular weight poly(alkylene) or a poly(carboxymethylcellulose). A dosage form is disclosed and claimed comprising the composition of matter for displacing an opioid analgesic from the dosage form.
514 Citations
19 Claims
-
1. An osmotic dosage form comprising:
-
(a) a wall comprising a semipermeable composition, which wall surrounds; (b) a bilayer core comprising; (i) a first layer comprising 75 ng to 750 mg of an analgesic opioid; (ii) a second push-displacement layer in bilayered contact with the first layer comprising 40 to 99 wt % of a poly(alkylene oxide) possessing a number-average molecular weight to 10,000,000, and 0.25 to 25 wt % of a hydroxyalkylcellulose possessing a number-average molecular weight to 75,000, and wherein the second layer is characterized by comprising 0.75 to 10 wt % of an antagonist selected from the group consisting of naltrexone, naloxone, nalmefene, nalide, nalmexone, nalorphine and nalbuphine; and
,(c) an exit in the wall in contact with the first layer comprising the analgesic opioid for the push-displacement layer to push the first layer comprising the analgesic opioid through the exit from the dosage form. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. An osmotic dosage form comprising:
-
(a) a wall comprising a semipermeable composition, which wall surrounds; (b) a bilayer core comprising; (i) a first layer comprising 75 ng to 750 mg of an analgesic opioid; (ii) a second push-displacement layer in contact with the first layer comprising 20 to 99 wt % of a poly(carboxymethylcellulose) comprising a number-average molecular weight to 2,500,000; and
0.25 to 25 wt % of a hydroxyalkylcellulose possessing a number-average molecular weight to 75,000, and wherein the second layer is characterized by comprising 0.75 to 10 wt % of an antagonist selected from the group consisting of naltrexone, naloxone, nalmefene, nalide, nalmexone, nalorphine and nalbuphine; and
,(c) an exit in the wall in contact with the first layer for releasing the analgesic opioid by the push-displacement layer pushing the analgesic opioid through the exit from the dosage form. - View Dependent Claims (9, 10, 11, 12, 13)
-
- 14. A composition comprising 10 ng to 275 mg of naloxone and 15 to 750 mg of a poly(alkylene oxide) comprising a molecular weight to 10,000,000.
- 16. A composition comprising 10 ng to 275 mg of naloxone and 15 to 750 mg of a poly(alkylene oxide) comprising a molecular weight to 2,500,000.
-
18. A composition of matter comprising 10 ng to 275 mg of naloxone, 15 to 750 mg of a poly(alkylene oxide) comprising a molecular weight to 10,000,000, 5 to 350 mg of an osmagent, and 0.05 to 7.5 mg of an antioxidant.
-
19. A composition of matter comprising 10 ng to 275 mg of naloxone, 15 to 750 mg of a poly(carboxymethylcellulose) comprising a molecular weight to 2,500,000, 5 to 350 mg of an osmagent, and 0.05 to 7.5 mg of an antioxidant.
Specification